noxopharm.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Noxopharm |
| Description | Pioneering life-changing therapies through innovative Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company. The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug |
| Keywords | noxopharm, pharmorage, veyonda, mRNA, Dr Gisela Mautner, drug development, biotechnology, biotech, clinical research, clinical trials, cancer treatment, septic shock, iso flavonoids, clinical development, pancreatic cancer, Glioblastoma |
Server Information
| WebSite | |
| Host IP | 54.79.107.72 |
| Location | Australia |
Related Websites
| Site | Rank |
More to Explore
noxopharm.com Valuation
|
US$2,219,009
Last updated: 2023-04-28 21:10:13
noxopharm.com has Semrush global rank of 4,769,835. noxopharm.com has an estimated worth of US$ 2,219,009, based on its estimated Ads revenue. noxopharm.com receives approximately 256,040 unique visitors each day. Its web server is located in Australia, with IP address 54.79.107.72. According to SiteAdvisor, noxopharm.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$2,219,009 |
| Daily Ads Revenue | US$2,049 |
| Monthly Ads Revenue | US$61,450 |
| Yearly Ads Revenue | US$737,394 |
| Daily Unique Visitors | 17,070 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| noxopharm.com. | A | 297 | IP: 54.79.107.72 |
| noxopharm.com. | NS | 3600 | NS Record: ns3.netregistry.net. |
| noxopharm.com. | NS | 3600 | NS Record: ns1.netregistry.net. |
| noxopharm.com. | NS | 3600 | NS Record: ns2.netregistry.net. |
| noxopharm.com. | MX | 3600 | MX Record: 100 in.hes.trendmicro.com. |
| noxopharm.com. | MX | 300 | MX Record: 0 noxopharm-com.mail.protection.outlook.com. |
| noxopharm.com. | TXT | 3600 | TXT Record: google-site-verification=uMUBR97DWOlkH00IWYhSUMfyfDrFxOSIqwDfbAgfLj4 |
| noxopharm.com. | TXT | 3600 | TXT Record: v=spf1 include:spf.hes.trendmicro.com include:spf.protection.outlook.com ~all |
| noxopharm.com. | TXT | 3600 | TXT Record: MS=ms88149960 |
| noxopharm.com. | TXT | 3600 | TXT Record: hes=5edd4e26b6a5ffe3bbe1d106e6fec6ab |
HtmlToTextCheckTime:2023-04-28 21:10:13
| Home About Us About Noxopharm CEO’s Message Management Team Board of Directors Scientific Advisors Our Network ASX Announcements Financial Reports Corporate Governance Sustainability Technology Technology Platforms Chroma™ Sofra™ Veyonda ® Regulatory Environment White Paper & Research Clinical Trials Ongoing Trials DARRT IONIC CEP Completed Trials LuPIN NOXCOVID Publications Investors Contact Us Contact Us Partnering Working at Noxopharm ASX Announcements Email Alerts Pioneering life-changing therapies through innovative science --> Learn more --> discover more --> --> LATEST NEWS .. --> .. .. --> LATEST NEWS 14 September 2022 Noxopharm reveals encouraging new pancreatic cancer preclinical study data --> --> WHO WE ARE Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines. We have three active drug development |
HTTP Headers
HTTP/1.1 301 Moved Permanently Content-Length: 142 Content-Type: text/html; charset=utf-8 Location: http://www.noxopharm.com/ Strict-Transport-Security: max-age=31536000 Date: Thu, 21 Oct 2021 20:52:35 GMT HTTP/1.1 302 Found Cache-Control: private Cache-control: no-cache="set-cookie" Content-Length: 131 Content-Type: text/html; charset=utf-8 Date: Thu, 21 Oct 2021 20:52:35 GMT Location: /site/content/ Set-Cookie: AWSELB=6513754B1C5CC94C36D4FA97FE6911DC2DDBF7E46578628D015A9121F2184A1C3FF9BF0642C27E7A01616814D2D5248271BDE8AF0BEC647D418D1169CD37248CA537D3FA62;PATH=/;MAX-AGE=600 Strict-Transport-Security: max-age=31536000 Connection: keep-alive HTTP/1.1 302 Found Cache-control: no-cache="set-cookie" Content-Length: 156 Content-Type: text/html; charset=utf-8 Date: Thu, 21 Oct 2021 20:52:35 GMT Location: https://www.noxopharm.com/site/content/ Set-Cookie: AWSELB=6513754B1C5CC94C36D4FA97FE6911DC2DDBF7E465F080A728F3B5B668C02DDFEF36CD5A71C27E7A01616814D2D5248271BDE8AF0B06B7ECAAD740E2288EEE78DA66F8C697;PATH=/;MAX-AGE=600 Strict-Transport-Security: max-age=31536000 Connection: keep-alive HTTP/2 200 cache-control: private content-length: 50284 content-type: text/html; charset=utf-8 set-cookie: ASP.NET_SessionId=1u5t1mqalweu2yscmq0vxwmm; path=/; secure; HttpOnly; SameSite=Lax strict-transport-security: max-age=31536000 date: Thu, 21 Oct 2021 20:52:36 GMT |
noxopharm.com Whois Information
Domain Name: NOXOPHARM.COM Registry Domain ID: 1970797143_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.enom.com Registrar URL: http://www.enomdomains.com Updated Date: 2018-10-22T22:24:26Z Creation Date: 2015-10-22T01:19:18Z Registry Expiry Date: 2027-10-22T01:19:18Z Registrar: eNom, LLC Registrar IANA ID: 48 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS1.NETREGISTRY.NET Name Server: NS2.NETREGISTRY.NET Name Server: NS3.NETREGISTRY.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-10T15:56:55Z <<< |